Healthy Adult Subjects Clinical Trial
Official title:
Pharmacokinetics and Bioavailability of Curcumin UP 30 Capsules in Healthy Adult Subjects: an Open, Randomized, Single-dose, Two-period, Two-sequence Crossover Study
A single-center, open-label, randomized, two-period, crossover study design of pharmacokinetics and bioavailability in healthy adult male and female subjects under fasting conditions.
Upgraded curcumin capsules(CuminUP30) is made from curcumin with a natural extraction content of 95% and excipients through physical process microprocessing, with a curcumin content of more than 30%. CuminUP30 capsules are 500 mg/ capsules and ordinary curcumin capsules are 450 mg/ capsules. The main purpose of this study is to evaluate the bioavailability by comparing the pharmacokinetics of CuminUP30 capsule with that of curcumin capsule before the prescription improvement. 12 cases are planned to be enrolled.According to the random table, each subject will be randomly assigned to one of two groups (group 1: A/B, group 2: B/A). The cleaning period between the two doses is 7 days. Subjects were given the test preparation (A) or the control preparation (B) on the first day of the first cycle of the trial, and were temporarily allowed to leave the phase I clinical research center after 72 hours of blood sample collection and vital signs examination after the completion of the medication. After a 7-day wash period, on the 8th day of the second cycle, the subject will be cross-administered with the control formulation (B) or the test formulation (A), all procedures are the same as in the first cycle. On the 11th day (the second cycle), subjects will undergo physical examination, ECG examination, assessment of vital signs (blood pressure, pulse, body temperature), laboratory examinations (blood biochemistry, blood routine, urine routine, detailed examination items are shown in the appendix 1) Female subjects must undergo a blood pregnancy test and then be allowed to leave the research center. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03267732 -
A Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518)
|
Phase 1 | |
| Completed |
NCT05040113 -
A Study On Human Mass Balance And Biotransformation
|
Phase 1 | |
| Completed |
NCT01433835 -
Safety and Pharmacokinetics of Single Oral Doses of MBX-400 in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT04029090 -
A Study to Evaluate the Effect of MCI-186 at Therapeutic and Supra-Therapeutic Doses on the QT Interval(QT)/Corrected QT Interval(QTc) Interval in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT04586985 -
Safety, Tolerability and Pharmacokinetics of FTX-6058
|
Phase 1 | |
| Completed |
NCT04481789 -
Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Males (Drug Interaction Study and Preliminary Regimen-Finding Study)
|
Phase 1 | |
| Completed |
NCT06107205 -
Bioequivalence of TTYP01 Tablets in Healthy Adult Subjects
|
Phase 1 | |
| Completed |
NCT04629131 -
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TNM002 in Healthy Adults
|
Phase 1 | |
| Recruiting |
NCT06063291 -
Single Ascending Oral Dose Phase 1 Study of ID110521156 in Healthy Adult Subjects
|
Phase 1 | |
| Completed |
NCT04203862 -
A Study of NPC-22 in Healthy Adult Males
|
Phase 1 | |
| Recruiting |
NCT05641181 -
A Trial of CRB4101 in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT04521192 -
Bioequivalence of Fluzoparib(SHR3162) Study on Healthy Chinese Adult Subjects
|
Phase 1 | |
| Completed |
NCT04400123 -
A Bioequivalence Study of Famitinib Malate on Healthy Chinese Volunteers
|
Phase 1 | |
| Completed |
NCT04811469 -
Safety, Tolerability and Pharmacokinetics of CBP-174 in Healthy Adults
|
Phase 1 | |
| Completed |
NCT04291846 -
A Food Effect Study of SHR1459 on Healthy Chinese Adult Subjects
|
Phase 1 | |
| Completed |
NCT01364441 -
Single-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ONO-2952 in Healthy Adult Subjects
|
Phase 1 | |
| Completed |
NCT02691702 -
Multiple Dose Study Of BIIB118 (PF-05251749) In Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT04493281 -
Bioequivalence Study of Oral Suspension and Intravenous Formulation of Edaravone in Healthy Adult Subjects
|
Phase 1 | |
| Completed |
NCT01376063 -
Study to Investigate the Interaction Between FG-4592 and Rosiglitazone in Healthy Adult Subjects
|
Phase 1 | |
| Completed |
NCT04481750 -
Study of Oral Edaravone in Healthy Adult Males
|
Phase 1 |